124168-55-4

Basic information

• Product Name: (3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL
• Synonyms: (3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL
• CAS NO: 124168-55-4
• Molecular Formula: C₉H₇ClOS
• Molecular Weight: 198.67
• EINECS: 200-258-5
• Mol File: 124168-55-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL(124168-55-4)
• EPA Substance Registry System: (3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL(124168-55-4)

Safety Data

• Hazardous Substances Data: 124168-55-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL is used as a building block in the pharmaceutical industry for its ability to contribute to the development of new drugs and therapies. Its unique chemical structure allows for the creation of a wide range of medicinal compounds with potential applications in treating various health conditions.
Used in Agrochemical Development:
In the agrochemical industry, (3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL is utilized as a key component in the synthesis of various agrochemical products. Its incorporation aids in the development of innovative solutions for agricultural challenges, such as pest control and crop protection.
Used in Medicinal Chemistry Research:
(3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL is employed as a research subject in the field of medicinal chemistry. Its biological and toxicological properties make it a valuable compound for studying the mechanisms of drug action, potential side effects, and the development of safer and more effective therapeutic agents.
Used in Organic Chemistry:
As a versatile building block in organic chemistry, (3-CHLORO-1-BENZOTHIEN-2-YL)METHANOL is used for the synthesis of a variety of chemical compounds. Its unique structure allows for the creation of new molecules with potential applications in various industries, including pharmaceuticals, materials science, and chemical manufacturing.

Upstream product

• 21211-22-3 3-chloro-1-benzothiophene-2-carboxylic acid 
• 14006-54-3 3-chloro-1-benzothiophen-2-carbaldehyde 
• 21211-07-4 3-chlorobenzo[b]thiophene-2-carboxylic acid methyl ester 
• 33775-94-9 2-(methylthio)iodobenzene 

Downstream Products

• 59812-38-3 (3-chloro-1-benzothiophen-2-yl)(phenyl)methanone 
• 691901-23-2 4-[(3-chlorobenzo[b]thien-2-yl)methoxy]benzenepropanoic acid 
• 1061606-27-6 3-(3-chloro-benzo[b]thiophen-2-ylmethoxy)-phthalic acid 
• 691901-21-0 methyl 4-[(3-chlorobenzo[b]thien-2-yl)methoxy]benzenepropanoate 
• 1061606-24-3 3-(3-chloro-benzo[b]thiophen-2-ylmethoxy)-phthalic acid dimethyl ester 
• 14006-54-3 3-chloro-1-benzothiophen-2-carbaldehyde 

Relevant articles and documents

Sodium halides as the source of electrophilic halogens in green synthesis of 3-halo- and 3,n-dihalobenzo[b]thiophenes

A convenient methodology for the synthesis of mono- and di-halogenated benzo[b]thiophenes is described herein, which utilizes copper(II) sulfate pentahydrate and various sodium halides in the presence of substituted 2-alkynylthioanisoles. The proposed met

Agents and methods for treating ischemic and other diseases

This invention relates to compounds that modulate TRPM7 protein activity and use of the same for treatment or prophylaxis of ischemia, cancer, pain or glaucoma.

Methods of treating soft tissue defects

The specification discloses compositions and methods for treating a soft tissue defect of an individual.

HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME

Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra', Rc, Rf, X2, Rd, Rd', Re, Re', m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.

COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS

The present specification discloses compositions and methods of transplanting tissue useful for treating a soft tissue condition of an individual.

METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS

The present invention relates to pyrimidine derivatives of Formula (Ia) and (Ib) (including tautomers, isomers, prodrugs, and pharmaceutically acceptable salts thereof). Said compounds are useful in the treatment of pain (such as neuropathic pain), inflammation, and epilepsy (by acting as anticonvulsants). Methods of medical treatment making use of said compounds, as well as additional compounds of Formula (IIa) and (IIb), are also disclosed.

4'-O-SUBSTITUTED ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME

Provided are 4'-O substituted isoindoline compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.

CETP INHIBITORS

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.

2,3,4-substituted cyclopentanones as therapeutic agents

Disclosed herein are compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, B, J, and E are further described. Methods, compositions, and medicaments related thereto are also disclosed.

2,3,4-Substituted cyclopentanones as therapeutic agents

Disclosed herein are compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, wherein a dashed line represents the presence or absence of a bond; Y is a carboxylic acid, sulfonic acid, or phosphonic acid functional group; or an amide or ester thereof comprising from 0 to 12 carbon atoms; or Y is hydroxymethyl or an ether thereof comprising from 0 to 12 carbon atoms; or Y is a tetrazolyl functional group; A is —(CH2)6—, cis —CH2—CH═CH—(CH2)3—, or —CH2—C≡C—(CH2)3— wherein 1 or 2 carbons may be substituted with S or O; B is hydrogen, C1-6 hydrocarbyl, CN, CO2H, or —(CH2)mX(CH2)pH, wherein m is at least 1 and the sum of m and p is from 1 to 5; X is S or O; J is H, CH3, or CF3; D is a covalent bond, CH2, O, or S; and E is an aromatic heterobicyclic ring system which may have substituents comprising up to 6 non-hydrogen atoms each. Methods, compositions, and medicaments related thereto are also disclosed.